We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Rivaroxaban treatment in patients who undergo transcatheter aortic valve replacement (TAVR) should be stopped and switched to standard of care.
MHRA has received a small number of reports suggesting lack of efficacy (thromboembolic events) in patients taking 15 mg or 20 mg rivaroxaban on an empty stomach; remind patients to take 15 mg or 20 mg rivaroxaban tablets wi…
Employment Tribunal decision.
There is an increased risk of myopathy associated with high-dose (80 mg) simvastatin. The 80-mg dose should be considered only in patients with severe hypercholesterolaemia and high risk of cardiovascular complications who h…
Prescribing information has been updated to introduce a lower recommended dose of 60 mg daily for patients with rheumatoid arthritis or ankylosing spondylitis.
Risk minimisation materials are available to support the safe use of new paediatric formulations of rivaroxaban (Xarelto) and dabigatran etexilate (Pradaxa). In addition, we ask healthcare professionals to consult the curren…
The profiles provide an overview of data on cardiovascular and cardiovascular related conditions of heart disease, stroke, diabetes and kidney disease. Data will be available for England, integrated care boards and upper tier local authorities where available.
Indication restricted to second-line treatment and contraindicated with some cardiovascular conditions and medicines Furthermore, cilostazol is now contraindicated in patients with any of the following: Unstable angina, recent myocardial infarction or coronary intervention (within…
Projects granted during 2016 that have a primary purpose of translational applied research - human cardiovascular disorders.
Increased risk of stroke in older women should be taken into account in prescribing decisions.
Data and analysis of cardiovascular disease (CVD) prevalence, variation, treatment and outcomes in the Hull CCG area.
Data and analysis of cardiovascular disease (CVD) prevalence, variation, treatment and outcomes in the West Essex CCG area.
Data and analysis of cardiovascular disease (CVD) prevalence, variation, treatment and outcomes in the Redditch and Bromsgrove CCG area.
Data and analysis of cardiovascular disease (CVD) prevalence, variation, treatment and outcomes in the Enfield CCG area.
Data and analysis of cardiovascular disease (CVD) prevalence, variation, treatment and outcomes in the Horsham and Mid Sussex CCG area.
Data and analysis of cardiovascular disease (CVD) prevalence, variation, treatment and outcomes in the Croydon CCG area.
Data and analysis of cardiovascular disease (CVD) prevalence, variation, treatment and outcomes in the Medway CCG area.
Data and analysis of cardiovascular disease (CVD) prevalence, variation, treatment and outcomes in the Birmingham South and Central CCG area.
Data and analysis of cardiovascular disease (CVD) prevalence, variation, treatment and outcomes in the Somerset CCG area.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).